9591815

Source:http://linkedlifedata.com/resource/pubmed/id/9591815

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0016299, umls-concept:C0017243, umls-concept:C0087111, umls-concept:C0288792, umls-concept:C0406317, umls-concept:C1378128
pubmed:issue	5 Pt 1
pubmed:dateCreated	1998-6-2
pubmed:abstractText	A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7907132
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents, http://linkedlifedata.com/resource/pubmed/chemical/Dermatologic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Fluocinonide, http://linkedlifedata.com/resource/pubmed/chemical/Gels, http://linkedlifedata.com/resource/pubmed/chemical/Glucocorticoids, http://linkedlifedata.com/resource/pubmed/chemical/Nicotinic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Prodrugs, http://linkedlifedata.com/resource/pubmed/chemical/tazarotene
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	0190-9622
pubmed:author	pubmed-author:AstEE, pubmed-author:CallenJ PJP, pubmed-author:ChandraratnaR ARA, pubmed-author:CullenS ISI, pubmed-author:GibsonJ RJR, pubmed-author:JouePP, pubmed-author:Kulp-ShortenC LCL, pubmed-author:LebwohlMM, pubmed-author:LoweN JNJ, pubmed-author:LueJ CJC, pubmed-author:PhillipsT JTJ, pubmed-author:QuellJ MJM, pubmed-author:RosenTT, pubmed-author:SeftonJJ, pubmed-author:WardT OTO
pubmed:issnType	Print
pubmed:volume	38
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	705-11
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:9591815-Administration, Cutaneous, pubmed-meshheading:9591815-Adolescent, pubmed-meshheading:9591815-Adult, pubmed-meshheading:9591815-Aged, pubmed-meshheading:9591815-Aged, 80 and over, pubmed-meshheading:9591815-Analysis of Variance, pubmed-meshheading:9591815-Anti-Inflammatory Agents, pubmed-meshheading:9591815-Child, pubmed-meshheading:9591815-Dermatologic Agents, pubmed-meshheading:9591815-Erythema, pubmed-meshheading:9591815-Female, pubmed-meshheading:9591815-Fluocinonide, pubmed-meshheading:9591815-Follow-Up Studies, pubmed-meshheading:9591815-Gels, pubmed-meshheading:9591815-Glucocorticoids, pubmed-meshheading:9591815-Humans, pubmed-meshheading:9591815-Life Tables, pubmed-meshheading:9591815-Male, pubmed-meshheading:9591815-Middle Aged, pubmed-meshheading:9591815-Nicotinic Acids, pubmed-meshheading:9591815-Prodrugs, pubmed-meshheading:9591815-Psoriasis, pubmed-meshheading:9591815-Safety, pubmed-meshheading:9591815-Single-Blind Method, pubmed-meshheading:9591815-Skin, pubmed-meshheading:9591815-Treatment Outcome
pubmed:year	1998
pubmed:articleTitle	Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
pubmed:affiliation	Mount Sinai Medical Center, New York, New York 10029, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Multicenter Study